Discovery of 2-Pyridylureas as Glucokinase Activators

Journal of Medicinal Chemistry

Volumn 57, Issue 19, 2014, Pages 8180-8186

  Hinklin, Ronald J ^a   Aicher, Thomas D ^a,c   Anderson, Deborah A ^a   Baer, Brian R ^a   Boyd, Steven A ^a,d   Condroski, Kevin R ^a,e   DeWolf, Walter E ^a   Kraser, Christopher F ^a   McVean, Maralee ^a,f   Rhodes, Susan P ^a   Sturgis, Hillary L ^a   Voegtli, Walter C ^a,g   Williams, Lance ^a   Houze, Jonathan B ^b  

^a ARRAY BIOPHARMA INC   (United States)

^b AMGEN INC   (United States)

^c Lycera Corporation   (United States)

^d SAB: Knopp Biosciences LLC   (United States)

^e CELGENE CORPORATION   (United States)

^f PreClinical Research Services Inc   (United States)

^g WCV: Alexion Pharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 (3 METHOXYPROPYLTHIO) 3 (2 METHYLPYRIDIN 3 YLOXY) PYRIDIN 2 YL) 3 METHYLUREA; ANTIDIABETIC AGENT; ENZYME ACTIVATOR; GLUCOKINASE; UNCLASSIFIED DRUG; PYRIDINE DERIVATIVE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG ISOLATION; DRUG STRUCTURE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PROCESS OPTIMIZATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DRUG DEVELOPMENT; GLUCOSE TOLERANCE TEST; METABOLISM; SYNTHESIS;

ANIMALS; DRUG DISCOVERY; ENZYME ACTIVATORS; GLUCOKINASE; GLUCOSE TOLERANCE TEST; MICE, INBRED C57BL; PYRIDINES; UREA;

EID: 84907894097     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501204z     Document Type: Article

References (24)

1. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 2004, 27 (5) 1047-1053
2. Aicher, T. D.; Boyd, S. A.; McVean, M.; Celeste, A. Novel therapeutics and targets for the treatment of diabetes Expert Rev. Clin. Pharmacol. 2010, 3 (2) 209-229
3. Printz, R. L.; Magnuson, M. A.; Granner, D. K. Annu. Rev. Nutr. 1993, 13, 463
4. Matschinsky, F. M. Assessing the potential of glucokinase activators in diabetes therapy Nat. Rev. Drug Discovery 2009, 8, 399-416
5. Matschinsky, F. M.; Zelent, B.; Doliba, N.; Li, C.; Vanderkooi, J. M.; Naji, A.; Sarabu, R.; Grimsby, J. Glucokinase activators for diabetes therapy Diabetes Care 2011, 34, S236-S243
6. Matschinsky, F. M.; Magnuson, M. A., Eds. Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics; Frontiers in Diabetes, Vol. 16; Karger: New York, 2004.
7. Grimsby, J.; Sarabu, R.; Corbett, W. L.; Haynes, N. E.; Bizzarro, F. T.; Coffey, J. W.; Guertin, K. R.; Hilliard, D. W.; Kester, R. F.; Mahaney, P. E.; Marcus, L.; Qi, L.; Spence, C. L.; Tengi, J.; Magnuson, M. A.; Chu, C. A.; Dvorozniak, M. T.; Matschinsky, F. M.; Grippo, J. F. Allosteric activators of glucokinase: potential role in diabetes therapy Science 2003, 301, 370-3
8. Sarabu, R.; Berthel, S. J.; Kester, R. F.; Tilley, J. W. Glucokinase activators as new type 2 diabetic therapeutic agents Expert Opin. Ther. Pat. 2008, 18, 759-768
9. Sarabu, R.; Berthel, S. J.; Kester, R. F.; Tilley, J. W. Novel glucokinase activators: a patent review (2008-2010) Expert Opin. Ther. Pat. 2011, 21, 13-33
10. Filipski, K. J.; Pfefferkorn, J. A. A patent review of glucokinase activators and disruptors of the glucokinase-glucokinase regulatory protein interaction: 2011-2014 Expert Opin. Ther. Pat. 2014, 24, 875-891
11. Filipski, K. J.; Futatsugi, K.; Pfefferkorn, J. A.; Stevens, B. D. Glucokinase activators Pharm. Pat. Anal. 2012, 1, 301-311
12. Array BioPharma and Amgen Partner in Type 2 Diabetes [Press release]. http://www.amgen.com/media/mediaprdetail.jsp?releaseID=1365736 (2009).
13. ClinicalTrials.gov: A Study of LY2599506 in Patients with Type 2 Diabetes. Sponsor: Eli Lilly and Company. NLM Identifier: NCT01024244. http://clinicaltrials.gov/show/NCT01024244 (accessed Mar 11, 2014).
14. Sarabu, R.; Bizzarro, F. T.; Corbett, W. L.; Dvorozniak, M. T.; Geng, W.; Grippo, J. F.; Haynes, N.-E.; Hutchings, S.; Garofalo, L.; Guertin, K. R.; Hilliard, D. W.; Kabat, M.; Kester, R. F.; Ka, W.; Liang, Z.; Mahaney, P. E.; Marcus, L.; Matschinsky, F. M.; Moore, D.; Racha, J.; Radinov, R.; Ren, Y.; Qi, L.; Pignatello, M.; Spence, C. L.; Steele, T.; Tengi, J.; Grimsby, J. Discovery of piragliatinî - first glucokinase activator studied in type 2 diabetic patients J. Med. Chem. 2012, 55, 7021-7036
15. Pfefferkorn, J. A.; Guzman-Perez, A.; Litchfield, J.; Aiello, R.; Treadway, J. L.; Pettersen, J.; Minich, M. L.; Filipski, K. J.; Jones, C. S.; Tu, M.; Aspnes, G.; Risley, H.; Bian, J.; Stevens, B. D.; Bourassa, P.; Da'Aquila, T.; Baker, L.; Barucci, N.; Robertson, A. S.; Bourbonais, F.; Derksen, D. R.; MacDougall, M.; Cabrera, O.; Chen, J.; Lapworth, A. L.; Landro, J. A.; Zavadoski, W. J.; Atkinson, K.; Haddish-Berhane, N.; Tan, B.; Yao, L.; Kosa, R. E.; Varma, M. V.; Feng, B.; Duignan, D. B.; El-Kattan, A.; Murdande, S.; Liu, S.; Ammirati, M.; Knafels, J.; Dasilva-Jardine, P.; Sweet, L.; Liras, S.; Rolph, T. P. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1 H -imidazol-1-yl) propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus J. Med. Chem. 2012, 55, 1318-1333
16. Wilding, J. P. H.; Leonsson-Zachrisson, M.; Wessman, C.; Johnsson, E. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin Diabetes Obes. Metab. 2013, 15, 750-759
17. Meininger, G. E.; Scott, R.; Alba, M.; Shentu, Y.; Luo, E.; Amin, H.; Davies, M. J.; Kaufman, K. D.; Goldstein, B. J. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes Diabetes Care 2011, 34, 2560-2566
18. Lu, M.; Li, P.; Bandyopadhyay, G.; Lagakos, W.; DeWolf, W. E., Jr; Alford, T.; Chicarelli, M. J.; Williams, L.; Anderson, D. A.; Baer, B. R.; McVean, M.; Conn, M.; Veniant, M. M.; Coward, P. Characterization of a novel glucokinase activator in rat and mouse models PLoS One 2014, 9 (2) e88431
19. Wood, M. R.; Anthony, N. J.; Buck, M. G.; Kuduk, S. D. WO200563690, 2005.
20. Cooke, A. J.; Edwards, A. S.; Andrews, F. E.; Bennett, D. J.; Nimz, O.; Carswell, E. L. WO2009138438, 2009.
21. Itoh, T.; Mase, T. A general palladium-catalyzed coupling of aryl bromides/triflates and thiols Org. Lett. 2004, 6, 4587-4590
22. Avalos, M.; Babiano, R.; Barneto, J. L.; Cintas, P.; Clemente, F. R.; Jimenez, J. L.; Palacios, J. C. Conformation of secondary amides. A predictive algorithm that correlates DFT-calculated structures and experimental proton chemical shifts J. Org. Chem. 2003, 68, 1834-1842
23. Kuhn, B.; Mohr, P.; Stahl, M. Intramolecular hydrogen bonding in medicinal chemistry J. Med. Chem. 2010, 53, 2601-2611
24. Grimsby, J.; Berthel, S. J.; Sarabu, R. Glucokinase activators for the potential treatment of type 2 diabetes Curr. Top. Med. Chem. 2008, 8, 1524-1532